Allarity Therapeutics (ALLR) Stock: Buy, Sell, or Hold?
ALLR - Allarity Therapeutics, Inc. Common Stock
$0.86
-0.02 (-2.23%)
▼
5d:
+3.28%
30d:
-17.31%
90d:
-27.73%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When ALLR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALLR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ALLR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ALLR is currently trading at $0.86, which is considered oversold relative to its 30-day fair value range of $0.89 to $1.11.
Technical Outlook: Technically, ALLR is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.04.
Market Sentiment: ALLR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.00 (+1150.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALLR is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.04.
Market Sentiment: ALLR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.00 (+1150.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.89 -
$1.11
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1150.6% below Wall St target ($11.00)
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.89 -
$1.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.04
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.02
Wall Street Target
$11.00
(+1150.6%)
Share & Embed Analysis
Last updated: October 22, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
